Nextgen Biomed Ltd
Tel Aviv Stock Exchange NXGN.TA
Nextgen Biomed Ltd Free Cash Flow Yield on January 14, 2025: -86.96%
Nextgen Biomed Ltd Free Cash Flow Yield is -86.96% on January 14, 2025, a -104.32% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
-
Nextgen Biomed Ltd 52-week high Free Cash Flow Yield is -24.28% on December 20, 2024, which is 72.08% above the current Free Cash Flow Yield.
-
Nextgen Biomed Ltd 52-week low Free Cash Flow Yield is -109.82% on January 02, 2025, which is -26.29% below the current Free Cash Flow Yield.
-
Nextgen Biomed Ltd average Free Cash Flow Yield for the last 52 weeks is -73.25%.
Key data
| Date | Free Cash Flow Yield | Market Value Added (MVA) | Price to Book Ratio (P/B) | Price to Earnings Ratio (P/E) |
|---|
Market news
Loading...
Tel Aviv Stock Exchange: NXGN.TA
| CEO | Mr. Harel Hershtik |
| IPO Date | Aug. 12, 2002 |
| Location | Israel |
| Headquarters | 132 Azrieli Towers Round Building |
| Employees | 5 |
| Sector | Health Care |
| Industries | |
Description
Nextgen Biomed Ltd develops topical treatment for psoriasis. The company was formerly known as Sela Group.Com Ltd. and changed its name to Nextgen Biomed Ltd in February 2010. Nextgen Biomed Ltd was incorporated in 1990 and is based in Tel Aviv, Israel.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email